Repligen (NASDAQ:RGEN) Releases FY 2026 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.030-2.090 for the period, compared to the consensus earnings per share estimate of 2.000. The company issued revenue guidance of $813.0 million-$835.0 million, compared to the consensus revenue estimate of $819.5 million.

Repligen Stock Down 0.7%

Shares of Repligen stock opened at $131.06 on Tuesday. Repligen has a 52-week low of $100.99 and a 52-week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The business’s 50 day simple moving average is $132.21 and its 200 day simple moving average is $132.05. The firm has a market cap of $7.39 billion, a PE ratio of 145.62, a P/E/G ratio of 2.54 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts predict that Repligen will post 1.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Wolfe Research started coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective on the stock. Royal Bank Of Canada initiated coverage on Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $165.36.

Insider Activity

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Pacer Advisors Inc. raised its holdings in shares of Repligen by 2.5% in the 4th quarter. Pacer Advisors Inc. now owns 10,469 shares of the biotechnology company’s stock valued at $1,715,000 after acquiring an additional 256 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Repligen by 12.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 646,122 shares of the biotechnology company’s stock worth $105,874,000 after purchasing an additional 74,044 shares during the last quarter. Compound Planning Inc. purchased a new position in shares of Repligen during the fourth quarter valued at approximately $204,000. Invesco Ltd. increased its position in Repligen by 43.9% during the 4th quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock valued at $205,880,000 after purchasing an additional 383,399 shares during the period. Finally, Alpine Woods Capital Investors LLC bought a new position in Repligen in the fourth quarter worth about $1,005,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.